XTX Topco Ltd Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 79.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,670 shares of the biotechnology company's stock after selling 125,276 shares during the quarter. XTX Topco Ltd's holdings in BioCryst Pharmaceuticals were worth $241,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. Xponance Inc. grew its stake in shares of BioCryst Pharmaceuticals by 13.1% during the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock valued at $80,000 after buying an additional 1,505 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of BioCryst Pharmaceuticals by 19.4% in the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock worth $124,000 after buying an additional 2,644 shares during the period. Creative Planning lifted its stake in shares of BioCryst Pharmaceuticals by 5.9% in the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock valued at $375,000 after acquiring an additional 2,734 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in BioCryst Pharmaceuticals by 7.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company's stock valued at $388,000 after acquiring an additional 3,653 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on BCRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $15.60.

BioCryst Pharmaceuticals Trading Up 1.1 %

Shares of BCRX stock traded up $0.08 during trading hours on Thursday, reaching $7.39. The company's stock had a trading volume of 2,017,481 shares, compared to its average volume of 2,842,392. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The stock has a market capitalization of $1.53 billion, a P/E ratio of -12.11 and a beta of 1.79. The firm's fifty day simple moving average is $7.62 and its 200 day simple moving average is $7.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter last year, the firm earned ($0.19) EPS. The business's revenue was up 35.1% on a year-over-year basis. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.